Stock Track | Applied Therapeutics Plunges 5.14% Pre-market After FDA Warning Letter on Genetic Disease Drug Trial

Stock Track

Dec 03, 2024

Applied Therapeutics Inc. (APLT) stock plummeted 5.14% in pre-market trading on Tuesday, following news that the company received a warning letter from the U.S. Food and Drug Administration (FDA) related to a trial studying its genetic disease drug.

The warning letter comes after the FDA declined to approve the company's treatment for the genetic disease last week, raising concerns over potential regulatory hurdles and setbacks in Applied Therapeutics' drug development plans.

The FDA's warning letter highlights issues with the company's clinical trial processes, which could delay or prevent the approval of its genetic disease treatment. Investors appear to be reacting negatively to this development, driving down Applied Therapeutics' stock price in anticipation of potential further challenges in bringing its drug to market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1122631794"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1122631794\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1122631794?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-03 17:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122631794","market":"us","top_or_hot":-1,"title":"Stock Track | Applied Therapeutics Plunges 5.14% Pre-market After FDA Warning Letter on Genetic Disease Drug Trial","media":"Stock Track","content":"<p>Applied Therapeutics Inc. (APLT) stock plummeted 5.14% in pre-market trading on Tuesday, following news that the company received a warning letter from the U.S. Food and Drug Administration (FDA) related to a trial studying its genetic disease drug.</p>\n\n<p>The warning letter comes after the FDA declined to approve the company's treatment for the genetic disease last week, raising concerns over potential regulatory hurdles and setbacks in Applied Therapeutics' drug development plans.</p>\n\n<p>The FDA's warning letter highlights issues with the company's clinical trial processes, which could delay or prevent the approval of its genetic disease treatment. Investors appear to be reacting negatively to this development, driving down Applied Therapeutics' stock price in anticipation of potential further challenges in bringing its drug to market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Applied Therapeutics Plunges 5.14% Pre-market After FDA Warning Letter on Genetic Disease Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Applied Therapeutics Plunges 5.14% Pre-market After FDA Warning Letter on Genetic Disease Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-12-03 17:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Applied Therapeutics Inc. (APLT) stock plummeted 5.14% in pre-market trading on Tuesday, following news that the company received a warning letter from the U.S. Food and Drug Administration (FDA) related to a trial studying its genetic disease drug.</p>\n\n<p>The warning letter comes after the FDA declined to approve the company's treatment for the genetic disease last week, raising concerns over potential regulatory hurdles and setbacks in Applied Therapeutics' drug development plans.</p>\n\n<p>The FDA's warning letter highlights issues with the company's clinical trial processes, which could delay or prevent the approval of its genetic disease treatment. Investors appear to be reacting negatively to this development, driving down Applied Therapeutics' stock price in anticipation of potential further challenges in bringing its drug to market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APLT","symbol_name":"Applied Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1122631794","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122631794","pubTimestamp":1733218030,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Applied Therapeutics Inc.  stock plummeted 5.14% in pre-market trading on Tuesday, following news that the company received a warning letter from the U.S. Food and Drug Administration  related to a trial studying its genetic disease drug.The warning letter comes after the FDA declined to approve the company's treatment for the genetic disease last week, raising concerns over potential regulatory hurdles and setbacks in Applied Therapeutics' drug development plans.The FDA's warning letter highlig","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APLT":"Applied Therapeutics Inc."},"translate_title":"FDA就遗传病药物试验发出警告信后，Applied Therapeutics盘前暴跌5.14%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLT":1},"content_text":"Applied Therapeutics Inc. (APLT) stock plummeted 5.14% in pre-market trading on Tuesday, following news that the company received a warning letter from the U.S. Food and Drug Administration (FDA) related to a trial studying its genetic disease drug.\nThe warning letter comes after the FDA declined to approve the company's treatment for the genetic disease last week, raising concerns over potential regulatory hurdles and setbacks in Applied Therapeutics' drug development plans.\nThe FDA's warning letter highlights issues with the company's clinical trial processes, which could delay or prevent the approval of its genetic disease treatment. Investors appear to be reacting negatively to this development, driving down Applied Therapeutics' stock price in anticipation of potential further challenges in bringing its drug to market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}